HERON THERAPEUTICS, INC. /DE/ Research and Development Expense
HERON THERAPEUTICS, INC. /DE/ (HRTX) reported Research and Development Expense of $2.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- HERON THERAPEUTICS, INC. /DE/ research and development expense for the quarter ending 2026-06-30 was $2.70M, a 7.91% decline year-over-year.
- HERON THERAPEUTICS, INC. /DE/ research and development expense for the quarter ending 2026-03-31 was $2.38M, a 4.65% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ research and development expense for the quarter ending 2025-12-31 was $3.75M, a 17.87% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ research and development expense for the quarter ending 2025-09-30 was $3.47M, a 22.28% decline year-over-year.
- HERON THERAPEUTICS, INC. /DE/ research and development expense for fiscal 2025 was $12.43M, a 25.50% decline from fiscal 2024.
- HERON THERAPEUTICS, INC. /DE/ research and development expense for fiscal 2024 was $16.68M, a 57.37% decline from fiscal 2023.
- HERON THERAPEUTICS, INC. /DE/ research and development expense for fiscal 2023 was $39.13M, a 52.68% decline from fiscal 2022.
- HERON THERAPEUTICS, INC. /DE/ research and development expense for fiscal 2022 was $82.70M, a 36.78% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.70M 10-Q · filed 2026-08-10 | $5.09M 10-Q · filed 2026-08-10 | $8.83M derived: sum of 3 quarters · filed 2026-08-10 | $12.30M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2026-03-31 | $2.38M 10-Q · filed 2026-05-11 | $6.13M derived: sum of 2 quarters · filed 2026-05-11 | $9.60M derived: sum of 3 quarters · filed 2026-05-11 | $12.54M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-12-31 | $3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.22M derived: sum of 2 quarters · filed 2026-02-26 | $10.15M derived: sum of 3 quarters · filed 2026-08-10 | $12.43M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $3.47M 10-Q · filed 2025-11-04 | $6.40M derived: sum of 2 quarters · filed 2026-08-10 | $8.68M 10-Q · filed 2025-11-04 | $11.86M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-06-30 | $2.93M 10-Q · filed 2026-08-10 | $5.21M 10-Q · filed 2026-08-10 | $8.39M derived: sum of 3 quarters · filed 2026-08-10 | $12.86M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-03-31 | $2.28M 10-Q · filed 2026-05-11 | $5.46M derived: sum of 2 quarters · filed 2026-05-11 | $9.92M derived: sum of 3 quarters · filed 2026-05-11 | $14.35M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $3.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.64M derived: sum of 2 quarters · filed 2026-02-26 | $12.07M derived: sum of 3 quarters · filed 2026-02-26 | $16.68M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $4.46M 10-Q · filed 2025-11-04 | $8.90M derived: sum of 2 quarters · filed 2025-11-04 | $13.51M 10-Q · filed 2025-11-04 | $21.31M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $4.43M 10-Q · filed 2025-08-08 | $9.04M 10-Q · filed 2025-08-08 | $16.84M derived: sum of 3 quarters · filed 2026-02-26 | $26.13M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $4.61M 10-Q · filed 2025-05-06 | $12.41M derived: sum of 2 quarters · filed 2026-02-26 | $21.70M derived: sum of 3 quarters · filed 2026-02-26 | $34.91M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $7.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $17.09M derived: sum of 2 quarters · filed 2026-02-26 | $30.30M derived: sum of 3 quarters · filed 2026-02-26 | $39.13M 10-K · filed 2026-02-26 | $55.90M 10-K · filed 2024-03-12 | |||
| 2023-09-30 | $9.29M 10-Q · filed 2024-11-12 | $13.56M 10-Q · filed 2023-11-14 | $22.50M derived: sum of 2 quarters · filed 2024-11-12 | $31.33M 10-Q · filed 2024-11-12 | $44.95M 10-Q · filed 2023-11-14 | $17.59M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | $13.21M 10-Q · filed 2024-08-06 | $17.57M 10-Q · filed 2023-08-14 | $22.05M 10-Q · filed 2024-08-06 | $31.39M 10-Q · filed 2023-08-14 | $8.30M derived: sum of 3 quarters · filed 2025-02-27 | $33.85M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | $8.84M 10-Q · filed 2024-05-07 | $13.82M 10-Q · filed 2023-05-11 | -$4.91M derived: sum of 2 quarters · filed 2025-02-27 | $20.64M derived: sum of 3 quarters · filed 2025-02-27 | $49.47M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2022-12-31 | -$13.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $11.80M derived: sum of 2 quarters · filed 2025-02-27 | $40.63M derived: sum of 3 quarters · filed 2025-02-27 | $82.70M 10-K · filed 2025-02-27 | $107.51M 10-K · filed 2023-03-29 | |||
| 2022-09-30 | $25.55M 10-Q · filed 2023-11-14 | $54.38M derived: sum of 2 quarters · filed 2023-11-14 | $96.45M 10-Q · filed 2023-11-14 | $125.33M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $28.83M 10-Q · filed 2023-08-14 | $70.90M 10-Q · filed 2023-08-14 | $99.78M derived: sum of 3 quarters · filed 2023-08-14 | $128.38M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $42.07M 10-Q · filed 2023-05-11 | $70.95M derived: sum of 2 quarters · filed 2023-05-11 | $99.54M derived: sum of 3 quarters · filed 2023-05-11 | $134.78M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $28.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $57.47M derived: sum of 2 quarters · filed 2023-03-29 | $92.70M derived: sum of 3 quarters · filed 2023-03-29 | $130.82M 10-K · filed 2023-03-29 | ||||
| 2021-09-30 | $28.59M 10-Q · filed 2022-11-08 | $63.83M derived: sum of 2 quarters · filed 2022-11-08 | $101.94M 10-Q · filed 2022-11-08 | $146.40M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | $35.23M 10-Q · filed 2022-08-09 | $73.35M 10-Q · filed 2022-08-09 | $117.80M derived: sum of 3 quarters · filed 2022-08-09 | $166.98M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | $38.12M 10-Q · filed 2022-05-09 | $82.57M derived: sum of 2 quarters · filed 2022-05-09 | $131.75M derived: sum of 3 quarters · filed 2022-05-09 | $175.75M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $44.45M 10-K · filed 2021-02-24 | $93.64M derived: sum of 2 quarters · filed 2021-11-03 | $137.64M derived: sum of 3 quarters · filed 2021-11-03 | $174.53M 10-K · filed 2022-02-28 | ||||
| 2020-09-30 | $49.18M 10-Q · filed 2021-11-03 | $93.19M derived: sum of 2 quarters · filed 2021-11-03 | $130.08M 10-Q · filed 2021-11-03 | $178.36M derived: sum of 4 quarters · filed 2021-11-03 | ||||
| 2020-06-30 | $44.00M 10-Q · filed 2021-08-09 | $80.90M 10-Q · filed 2021-08-09 | $129.18M derived: sum of 3 quarters · filed 2021-08-09 | $163.88M derived: sum of 4 quarters · filed 2021-08-09 | ||||
| 2020-03-31 | $36.89M 10-Q · filed 2021-05-10 | $85.17M derived: sum of 2 quarters · filed 2021-05-10 | $119.88M derived: sum of 3 quarters · filed 2021-05-10 | $161.30M derived: sum of 4 quarters · filed 2021-05-10 | ||||
| 2019-12-31 | $48.28M 10-K · filed 2021-02-24 | $82.98M derived: sum of 2 quarters · filed 2021-02-24 | $124.41M derived: sum of 3 quarters · filed 2021-02-24 | $167.38M 10-K · filed 2022-02-28 | ||||
| 2019-09-30 | $34.71M 10-K · filed 2021-02-24 | $76.13M derived: sum of 2 quarters · filed 2021-02-24 | $119.11M 10-Q · filed 2020-11-05 | $159.00M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-06-30 | $41.42M 10-K · filed 2021-02-24 | $84.40M 10-Q · filed 2020-08-05 | $124.29M derived: sum of 3 quarters · filed 2021-02-24 | $154.71M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-03-31 | $42.97M 10-K · filed 2021-02-24 | $82.86M derived: sum of 2 quarters · filed 2021-02-24 | $113.28M derived: sum of 3 quarters · filed 2021-02-24 | $143.44M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2018-12-31 | $39.89M 10-K · filed 2020-03-02 | $70.31M derived: sum of 2 quarters · filed 2020-03-02 | $100.47M derived: sum of 3 quarters · filed 2020-03-02 | $140.03M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | $30.42M 10-K · filed 2020-03-02 | $60.58M derived: sum of 2 quarters · filed 2020-03-02 | $100.14M 10-Q · filed 2019-11-12 | $147.90M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-06-30 | $30.16M 10-K · filed 2020-03-02 | $69.72M 10-Q · filed 2019-08-05 | $117.48M derived: sum of 3 quarters · filed 2020-03-02 | $146.32M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-03-31 | $39.56M 10-K · filed 2020-03-02 | $87.32M derived: sum of 2 quarters · filed 2020-03-02 | $116.16M derived: sum of 3 quarters · filed 2020-03-02 | $144.76M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2017-12-31 | $47.76M 10-K · filed 2019-02-22 | $76.60M derived: sum of 2 quarters · filed 2019-02-22 | $105.20M derived: sum of 3 quarters · filed 2019-02-22 | $138.58M 10-K · filed 2020-03-02 | ||||
| 2017-09-30 | $28.84M 10-K · filed 2019-02-22 | $57.44M derived: sum of 2 quarters · filed 2019-02-22 | $90.83M 10-Q · filed 2018-11-07 | $120.33M derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2017-06-30 | $28.60M 10-K · filed 2019-02-22 | $61.98M 10-Q · filed 2018-08-08 | $91.49M derived: sum of 3 quarters · filed 2019-02-22 | $121.73M derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2017-03-31 | $33.38M 10-K · filed 2019-02-22 | $62.89M derived: sum of 2 quarters · filed 2019-02-22 | $93.13M derived: sum of 3 quarters · filed 2019-02-22 | $120.42M derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2016-12-31 | $29.50M 10-K · filed 2018-02-27 | $59.75M derived: sum of 2 quarters · filed 2018-02-27 | $87.03M derived: sum of 3 quarters · filed 2018-02-27 | $103.13M 10-K · filed 2019-02-22 | ||||
| 2016-09-30 | $30.24M 10-K · filed 2018-02-27 | $57.53M derived: sum of 2 quarters · filed 2018-02-27 | $73.62M 10-Q · filed 2017-11-06 | $89.88M derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2016-06-30 | $27.29M 10-K · filed 2018-02-27 | $43.38M 10-Q · filed 2017-08-09 | $59.64M derived: sum of 3 quarters · filed 2018-02-27 | $73.88M derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2016-03-31 | $16.09M 10-K · filed 2018-02-27 | $32.35M derived: sum of 2 quarters · filed 2018-02-27 | $46.60M derived: sum of 3 quarters · filed 2018-02-27 | $62.77M derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2015-12-31 | $16.26M 10-K · filed 2017-02-23 | $30.50M derived: sum of 2 quarters · filed 2017-02-23 | $46.68M derived: sum of 3 quarters · filed 2017-02-23 | $61.18M 10-K · filed 2018-02-27 | ||||
| 2015-09-30 | $14.24M 10-K · filed 2017-02-23 | $30.42M derived: sum of 2 quarters · filed 2017-02-23 | $44.92M 10-Q · filed 2016-11-08 | $59.12M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2015-06-30 | $16.18M 10-K · filed 2017-02-23 | $30.68M 10-Q · filed 2016-08-08 | $44.87M derived: sum of 3 quarters · filed 2017-02-23 | $59.60M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2015-03-31 | $14.50M 10-K · filed 2017-02-23 | $28.70M derived: sum of 2 quarters · filed 2017-02-23 | $43.43M derived: sum of 3 quarters · filed 2017-02-23 | $57.71M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2014-12-31 | $14.20M 10-K · filed 2016-02-19 | $28.93M derived: sum of 2 quarters · filed 2016-02-19 | $43.20M derived: sum of 3 quarters · filed 2016-02-19 | $54.83M 10-K · filed 2017-02-23 | ||||
| 2014-09-30 | $14.73M 10-K · filed 2016-02-19 | $29.01M derived: sum of 2 quarters · filed 2016-02-19 | $40.64M 10-Q · filed 2015-11-06 | $40.93M 10-Q · filed 2014-11-06 | $49.18M derived: sum of 4 quarters · filed 2016-02-19 | |||
| 2014-06-30 | $14.28M 10-K · filed 2016-02-19 | $14.43M 10-Q · filed 2014-08-04 | $25.91M 10-Q · filed 2015-08-07 | $26.20M 10-Q · filed 2014-08-04 | $34.45M derived: sum of 3 quarters · filed 2016-02-19 | $40.61M derived: sum of 4 quarters · filed 2016-02-19 | ||
| 2014-03-31 | $11.63M 10-K · filed 2016-02-19 | $11.77M 10-Q · filed 2014-05-12 | $20.17M derived: sum of 2 quarters · filed 2016-02-19 | $26.33M derived: sum of 3 quarters · filed 2016-02-19 | $37.08M derived: sum of 4 quarters · filed 2016-02-19 | |||
| 2013-12-31 | $8.54M 10-K · filed 2015-03-13 | $14.70M derived: sum of 2 quarters · filed 2015-03-13 | $25.45M derived: sum of 3 quarters · filed 2015-03-13 | $32.52M 10-K · filed 2016-02-19 | $32.78M 10-K · filed 2014-03-07 | |||
| 2013-09-30 | $6.17M 10-K · filed 2015-03-13 | $5.88M 10-Q · filed 2013-11-12 | $16.91M derived: sum of 2 quarters · filed 2015-03-13 | $24.16M 10-Q · filed 2014-11-06 | $23.19M 10-Q · filed 2013-11-12 | $29.20M derived: sum of 4 quarters · filed 2015-03-13 | ||
| 2013-06-30 | $10.75M 10-K · filed 2015-03-13 | $10.53M 10-Q · filed 2013-08-08 | $17.95M 10-Q · filed 2014-08-04 | $17.30M 10-Q · filed 2013-08-08 | $23.04M derived: sum of 3 quarters · filed 2015-03-13 | $26.67M derived: sum of 4 quarters · filed 2015-03-13 | ||
| 2013-03-31 | $7.14M 10-Q · filed 2014-05-12 | $6.77M 10-Q · filed 2013-05-10 | $12.29M derived: sum of 2 quarters · filed 2015-03-13 | $15.92M derived: sum of 3 quarters · filed 2015-03-13 | $18.98M derived: sum of 4 quarters · filed 2015-03-13 | |||
| 2012-12-31 | $5.15M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | $8.78M derived: sum of 2 quarters · filed 2015-03-13 | $11.85M derived: sum of 3 quarters · filed 2015-03-13 | $15.17M 10-K · filed 2015-03-13 | $15.04M 10-K · filed 2013-03-01 | |||
| 2012-09-30 | $3.63M 10-Q · filed 2013-11-12 | $6.69M derived: sum of 2 quarters · filed 2013-11-12 | $10.02M 10-Q · filed 2013-11-12 | $16.61M derived: sum of 4 quarters · filed 2015-03-13 | ||||
| 2012-06-30 | $3.07M 10-Q · filed 2013-08-08 | $6.40M 10-Q · filed 2013-08-08 | $12.99M derived: sum of 3 quarters · filed 2015-03-13 | $15.92M derived: sum of 4 quarters · filed 2015-03-13 | ||||
| 2012-03-31 | $7.07M 10-K · filed 2015-03-13 | $3.33M 10-Q · filed 2012-05-10 | $9.92M derived: sum of 2 quarters · filed 2015-03-13 | $12.85M derived: sum of 3 quarters · filed 2015-03-13 | $14.13M derived: sum of 4 quarters · filed 2015-03-13 | |||
| 2011-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07 | $5.78M derived: sum of 2 quarters · filed 2014-03-07 | $7.07M derived: sum of 3 quarters · filed 2014-03-07 | $8.21M 10-K · filed 2014-03-07 | ||||
| 2011-09-30 | $2.93M 10-Q · filed 2012-11-05 | $4.21M derived: sum of 2 quarters · filed 2012-11-05 | $5.35M 10-Q · filed 2012-11-05 | $6.85M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2011-06-30 | $1.28M 10-Q · filed 2012-08-09 | $2.42M 10-Q · filed 2012-08-09 | $3.92M derived: sum of 3 quarters · filed 2013-03-01 | $5.47M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2011-03-31 | $1.14M 10-Q · filed 2012-05-10 | $2.64M derived: sum of 2 quarters · filed 2013-03-01 | $4.18M derived: sum of 3 quarters · filed 2013-03-01 | $6.07M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2010-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $3.04M derived: sum of 2 quarters · filed 2013-03-01 | $4.93M derived: sum of 3 quarters · filed 2013-03-01 | $7.26M 10-K · filed 2013-03-01 | ||||
| 2010-09-30 | $1.54M 10-Q · filed 2011-11-07 | $3.43M derived: sum of 2 quarters · filed 2011-11-07 | $5.76M 10-Q · filed 2011-11-07 | |||||
| 2010-06-30 | $1.89M 10-Q · filed 2011-08-08 | $4.22M 10-Q · filed 2011-08-08 | ||||||
| 2009-12-31 | $7.80M 10-K · filed 2012-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |